Positron Emission Tomography (PET) represents a step forward in the definition of response to therapy in patients with Hodgkin Lymphoma (HL). In particular the use of PET for the early assessment of response has been described as the most important tool for predicting the risk of disease progression. As no data are available to support the use of early assessment of response for adapting and modifying subsequent treatment, the use of PET should be limited only to patients enrolled in clinical trials. Irrespective of recommendations PET scanning is included in the current management of patients with HL at baseline, mid treatment, end of treatment, and follow-up. So far no study has been performed to verify how PET is currently used in the clinical setting and to assess if and how results of PET scanning are used for supporting treatment and clinical decisions.
Study Type
OBSERVATIONAL
Enrollment
136
PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
Registro Tumori di Modena
Modena, Modena, Italy
Progression-free survival
Time frame: within 1 month after end of treatment
Overall survival
Time frame: within 1 month after end of treatment
Disease-free survival
Time frame: within 1 month after end of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.